Gracell Biotechnologies Inc. GRCL
At closeFeb 21, 2024, 4:00 PM EST
52-week range unavailable
- Market cap
- 197.97M
- Shares out
- 96.57M
- Forward P/E
- -56.94
- Volume
- 6.37M
- Open
- 10.26
- Previous close
- 10.25
- Day's range
- 10.17 – 10.28
- Beta
- -0.34
- Analysts
- Hold
- Price target
- 10.58 (+3.2%)
- Earnings date
- Mar 11, 2024
Key statistics
- Enterprise value
- 3.32B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 1.71B
- Total debt
- 115.82M
- Return on equity
- -31.57%
- Short % of float
- 1.97%
- 50-day average
- 9.54
- 200-day average
- 5.24
Analyst view
Consensus: hold
- Target (low)
- 10.00
- Target (mean)
- 10.58
- Target (high)
- 11.50
- Strong buy2
- Buy3
- Hold4
- Sell0
- Strong sell0
Next earnings
Mar 11, 2024
Expected Mar 11, 2024. Consensus EPS estimate -0.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2024 | Dec 1, 2023 | -0.21 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.26 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.37 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.35 | — | — | — |
| Mar 13, 2023 | Dec 1, 2022 | -0.43 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.09 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 18, 2023 | Stifel | init | — | Buy |
| Sep 4, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 29, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 28, 2023 | Citigroup | main | Buy | Buy |
| Aug 13, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 12, 2023 | BTIG | main | Buy | Buy |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- gracellbio.com
News
Gracell Biotechnologies Acquisition Completed 
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement 
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma 
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy? 
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL 
Yes Virginia, There Is a Santa Claus Rally 
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders 
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases 
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Your note
Sign in to keep a note on GRCL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Temasek Holdings (Private) Limited | 10.32% | 9,901,940 | 37.73M | Jun 29, 2023 |
| Orbimed Advisors LLC. | 9.42% | 9,033,726 | 34.42M | Jun 29, 2023 |
| Vivo Capital, LLC | 4.14% | 3,969,427 | 15.12M | Jun 29, 2023 |
| Great Point Partners LLC | 2.36% | 2,268,057 | 8.64M | Jun 29, 2023 |
| Logos Global Management LP | 1.88% | 1,800,000 | 6.86M | Jun 29, 2023 |
| Sphera Funds Management Ltd. | 1.28% | 1,228,665 | 4.68M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares NASDAQ Biotechnology ETF | 0.33% | 319,780 | 1.05M | Aug 30, 2023 |
| Blackrock Large Cap Ser Fds-Blackrock Event Driven Equity Fd | 0.07% | 64,671 | 177.20K | May 30, 2023 |
| Invesco ETF Tr-Invesco Golden Dragon China ETF | 0.06% | 59,178 | 194.10K | Aug 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 33,164 | 90.87K | May 30, 2023 |
| SPDR Portfolio Emerging Markets ETF | 0.01% | 12,598 | 41.32K | Aug 30, 2023 |